OlympiA: What the Breast Cancer Trial Found

The first PARP inhibitor tested after surgery

PARP inhibitors were established in advanced breast cancer before OlympiA. The question here was different, and harder to answer: could one of them be used earlier, after surgery, to stop the cancer coming back at all?

Trials in that setting take years, because you are waiting for events that may never happen. OlympiA reported its first result at a pre-specified interim analysis, and its survival result a year after that.

Who was eligible

Field	Detail
Trial	OlympiA
Identifier	NCT02032823
Phase	Phase 3
Design	Randomised, double-blind, placebo-controlled
Cancer type	HER2-negative early breast cancer with an inherited BRCA1 or BRCA2 variant and high-risk features
Comparator	One year of oral olaparib against placebo
Primary endpoint	Invasive disease-free survival

1,836 people were randomised, half to each side. Two things had to be true to join: a germline BRCA1 or BRCA2 pathogenic or likely pathogenic variant, and high-risk clinical or pathological features. Everyone had already completed local treatment and chemotherapy, given either before or after surgery. People with hormone-receptor-positive cancer took endocrine therapy alongside the study drug.

The three-year result

At a median follow-up of 2.5 years, 85.9% of the olaparib group were alive and free of invasive cancer at three years, against 77.1% on placebo — a difference of 8.8 percentage points (95% CI 4.5 to 13.0). The hazard ratio was 0.58 (99.5% CI 0.41 to 0.82, p<0.001).

Freedom from distant spread at three years was 87.5% against 80.4%, a difference of 7.1 points (95% CI 3.0 to 11.1), hazard ratio 0.57 (99.5% CI 0.39 to 0.83, p<0.001).

Safety matched what was already known about olaparib, with no excess of serious adverse events, and the drug had limited effect on overall reported quality of life.

Why the survival number was not called a win at first

There were fewer deaths on olaparib: 59 against 86, a hazard ratio of 0.68 (99% CI 0.44 to 1.05) with a p-value of 0.02.

The trial had set a threshold of p<0.01 for that interim look. A p-value of 0.02 does not clear it. Interim boundaries are deliberately strict, because a trial that takes many looks at its own data will eventually see a difference by chance. So the honest reading at that point was: fewer deaths, not yet a survival benefit.

What the second analysis showed

The pre-specified second interim analysis of survival was published in 2022, at a median follow-up of 3.5 years. This time the threshold was p<0.015, and the result cleared it: hazard ratio 0.68 (98.5% CI 0.47 to 0.97, p=0.009).

Four-year survival was 89.8% with olaparib and 86.4% with placebo, a difference of 3.4 percentage points (95% CI −0.1 to 6.8). Four-year invasive disease-free survival was 82.7% against 75.4%, and four-year distant disease-free survival 86.5% against 79.1%.

No new safety signals appeared. In particular, the 2022 report identified no new cases of acute myeloid leukaemia or myelodysplastic syndrome, which had been the specific long-term worry about this drug class.

What this trial cannot tell you

• Whether it helps lower-risk BRCA carriers. Eligibility required both the inherited variant and high-risk features.
• Whether olaparib could replace chemotherapy. Everyone here had already had chemotherapy; the drug was tested on top of it.
• What happens over a decade. Median follow-up was 2.5 years at the first report and 3.5 at the second, and breast cancer can recur much later than that.
• Whether one year is the right length. That was the protocol's choice, not a duration compared against others.

Questions about genetic testing and adjuvant treatment

• Has my BRCA status been tested, and was the change inherited?
• What high-risk features do I have, and do they match this trial's entry rules?
• What would a year on this drug involve, alongside anything else I am taking?

Sources

This article was written from the sources below, which were checked on the source-check date shown above.

• NEJM: Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer (OlympiA) (primary)
• Annals of Oncology: Overall Survival in the OlympiA Phase III Trial (primary)

How this article was prepared

Prepared by Cancer Explained's AI-assisted editorial system and checked against the sources listed below. This article has not been reviewed by a healthcare professional unless a named reviewer is specifically shown.

Cancer Explained is published by the National Cancer Information Foundation as a nonprofit-oriented public-interest education project. It is not a diagnostic service, does not recommend treatments, and is not for emergencies.

Found an error, a broken source link, outdated information, or wording that feels insensitive? Report it here — we log and act on material corrections.